BRIDGEWATER, N.J.--(BUSINESS WIRE)--As previously reported, NovaDel Pharma Inc. (NVDL.PK) is in the process of selling its assets in anticipation of liquidating the company and distributing its remaining cash to shareholders. Previously, Novadel has (i) sold its NovaMist™ patents and trademarks to SUDA LTD in exchange for cash and SUDA Common Stock and Options, (ii) sold its NitroMist™ patents and Trademarks and the NitroMist license to Akrimax, and (iii) entered into an agreement to sell the intellectual property and license to ECR for ZolpiMist™ for the assumption of the amount due to the FDA relating to ZolpiMist. This agreement is subject to the buyer obtaining financing. If financing is obtained, this sale should close by the end of April 2014.
Help employers find you! Check out all the jobs and post your resume.
